This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Top ETF Stories of Q1 of 2024
by Sanghamitra Saha
The S&P 500 just closed out best first quarter since 2019.
Best and Worst ETF Zones of Q1
by Sweta Killa
Bitcoin and the related stocks were the hottest throughout the first quarter amid growing optimism about the tokens.
The Zacks Analyst Blog Highlights CRPT, WEED, SMH, CNCR and KBWP
by Zacks Equity Research
CRPT, WEED, SMH, CNCR and KBWP are part of the Zacks top Analyst Blog.
4 Best ETF Areas of Q1
by Sanghamitra Saha
Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.
5 Market-Beating Sector ETFs of Q1
by Sweta Killa
Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
5 Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street delivered a downbeat performance last week.
Cannabis ETFs Jump on Imminent Rescheduling News
by Sweta Killa
Cannabis stocks & ETFs jumped on Mar 15 after a prominent hedge fund manager suggested that regulators will soon reclassify marijuana as a less dangerous drug.
Marijuana ETFs Breezing Past S&P 500: More Growth Ahead?
by Sanghamitra Saha
Cannabis stocks soared this year after the Department of Health and Human Services asked the US Drug Enforcement Administration to start reviewing its classification of cannabis from Schedule I to Schedule III. Positive developments are happening in Germany also.
4 Best ETFs of Record-Breaking Last Week
by Sanghamitra Saha
While Nvidia's ascent and strong earnings reports have buoyed investor confidence, ongoing developments in monetary policy and economic data will continue to shape market sentiment in the weeks and months ahead.
Best and Worst ETF Zones Through Halfway of Q1
by Sweta Killa
We have highlighted three ETFs, each from the best and worst-performing zones in the middle of first-quarter 2024.
5 Sector ETFs Beating the Market Halfway Through Q1
by Sweta Killa
A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.
Best & Worst ETFs of January
by Sanghamitra Saha
January proved to be a month of fluctuation for Wall Street. While concerns about reduced expectations for rate cuts had an adverse impact, the stock market saw a rally thanks to strong corporate earnings and renewed confidence in the tech sector.
Cannabis ETFs Outperform in January
by Sweta Killa
The cannabis industry has been performing well this year after the US Drug Enforcement Administration started reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
4 Best-Performing ETF Areas of Last Week
by Sanghamitra Saha
Wall Street was upbeat last week.
Cannabis ETFs: What's Behind the Latest Surge
by Neena Mishra
While marijuana ETFs have seen a recent surge, investors should be aware of the potential risks
Cannabis ETFs Spike on Marijuana Classification Review
by Sweta Killa
Marijuana stocks spiked following the report that the US Drug Enforcement Administration (¿¿¿DEA¿¿¿) is reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
Best-Performing ETFs of Last Week
by Sanghamitra Saha
The S&P 500 hit a new high for the year last week after the November jobs report and University of Michigan consumer survey data indicated a resilient economy and cooling inflation, triggering bets on a so-called soft-landing scenario.
5 ETF Areas At One-Month High to Start December
by Sanghamitra Saha
So far this month, Wall Street remained almost flat. But a few ETF areas have been hovering at around a month-high and have been still gaining strength.
The Zacks Analyst Blog Highlights ARK Innovation ETF, Roundhill Cannabis ETF, Kelly CRISPR & Gene Editing Technology ETF, Invesco Dorsey Wright Consumer Cyclicals Momentum ETF and iShares U.S. Home Construction ETF
by Zacks Equity Research
ARK Innovation ETF, Roundhill Cannabis ETF, Kelly CRISPR & Gene Editing Technology ETF, Invesco Dorsey Wright Consumer Cyclicals Momentum ETF and iShares U.S. Home Construction ETF are included in this Analyst Blog.
5 Sector ETFs That Beat the Market in November
by Sweta Killa
Wall Street has been on a stellar ride, with all three major indices on track to wrap up their best monthly performance of 2023.
Best Performing ETFs of Q3 2023
by Neena Mishra
These ETFs managed to shine in the challenging quarter
Top ETF Stories of September to Watch in October
by Sanghamitra Saha
These are the top ETF events in the month of September that could be under watch in October.
5 Sector ETFs That Survived the Market Downturn in September
by Sweta Killa
September has lived up to its reputation of a historically weak month for stocks. Despite the weakness, a few sectors have still been in green over the past month.
September Turns Out as Worst Month of 2023: ETF Winners
by Sanghamitra Saha
September is historically the worst month of the year for stocks. This year has been no exception with the S&P 500 and the Nasdaq logging the worst month of the year.